{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:40:06Z","timestamp":1756363206347,"version":"3.44.0"},"reference-count":15,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,8,29]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:p>This case report discusses a patient with systemic lupus erythematosus (SLE) treated with low-dose azathioprine who developed progressive multifocal leukoencephalopathy (PML). PML is a rare, severe, demyelinating disease linked to John Cunningham polyomavirus (JCV) reactivation.<\/jats:p>\n               <jats:p>Treated with pembrolizumab, an immune checkpoint inhibitor, the patient initially improved. However, after the fourth dose, her condition rapidly worsened resulting in treatment discontinuation and death. Similar cases highlight the complex interplay of factors in PML development in SLE patients, including immunosuppression and genetic factors. The use of pembrolizumab in PML and SLE necessitates careful consideration of potential complications.<\/jats:p>","DOI":"10.1136\/bcr-2024-260624","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T01:45:11Z","timestamp":1726796711000},"page":"e260624","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Progressive multifocal leukoencephalopathy in systemic lupus erythematosus treated with pembrolizumab"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1186-8628","authenticated-orcid":false,"given":"Matilde","family":"\u00d8rum","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark"},{"name":"Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Lund Laursen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark"},{"name":"Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Troldborg","sequence":"additional","affiliation":[{"name":"Aarhus University, Aarhus, Denmark"},{"name":"Department of Rheumatology, Aarhus University Hospital, Aarhus N, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"2025082723155058000_17.9.e260624.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00427-y"},{"key":"2025082723155058000_17.9.e260624.2","first-page":"617","article-title":"Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review","volume":"25","author":"Henegar","year":"2016","journal-title":"Lupus (Los Angel)"},{"key":"2025082723155058000_17.9.e260624.3","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000388","article-title":"Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus","volume":"7","author":"Kapoor","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025082723155058000_17.9.e260624.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.24966"},{"key":"2025082723155058000_17.9.e260624.5","doi-asserted-by":"publisher","DOI":"10.1159\/000444874"},{"key":"2025082723155058000_17.9.e260624.6","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31825a313c"},{"key":"2025082723155058000_17.9.e260624.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815039"},{"key":"2025082723155058000_17.9.e260624.8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.26512","article-title":"Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors","volume":"93","author":"Boumaza","year":"2023","journal-title":"Ann Neurol"},{"key":"2025082723155058000_17.9.e260624.9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10067-020-05258-2","article-title":"Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine","volume":"40","author":"Daniel","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025082723155058000_17.9.e260624.10","first-page":"1849","article-title":"Progressive multifocal leukoencephalopathy in systemic lupus erythematosus managed with pembrolizumab: A case report with literature review","volume":"30","author":"Lan","year":"2021","journal-title":"Lupus (Los Angel)"},{"key":"2025082723155058000_17.9.e260624.11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/imr.13247","article-title":"Immune\u2010related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol Rev"},{"key":"2025082723155058000_17.9.e260624.12","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(21)00167-8","article-title":"Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions","volume":"8","author":"Bennett","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025082723155058000_17.9.e260624.13","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000078","article-title":"Haematological manifestations of lupus","volume":"2","author":"Fayyaz","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2025082723155058000_17.9.e260624.14","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12216945","article-title":"Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus: A Consequence of Patient-Intrinsic or -Extrinsic Factors?","volume":"12","author":"Emmanouilidou","year":"2023","journal-title":"J Clin Med"},{"key":"2025082723155058000_17.9.e260624.15","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-260624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:15:57Z","timestamp":1756361757000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-260624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,19]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bcr-2024-260624"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-260624","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}